| Market Capitalization (Millions $) |
4,839 |
| Shares
Outstanding (Millions) |
173 |
| Employees |
798 |
| Revenues (TTM) (Millions $) |
1,095 |
| Net Income (TTM) (Millions $) |
376 |
| Cash Flow (TTM) (Millions $) |
146 |
| Capital Exp. (TTM) (Millions $) |
10 |
Business Description
Acadia Pharmaceuticals Inc is a publicly traded biopharmaceutical company, founded in 1997 in San Diego, California, USA. The company's primary focus is on developing and commercializing drugs that address unmet medical needs in central nervous system (CNS) disorders, such as Parkinson's disease, Alzheimer's disease, schizophrenia, and depression.
Acadia's flagship drug is pimavanserin, which is marketed as Nuplazid. It is the first and only FDA-approved treatment for Parkinson's disease psychosis, a condition that affects up to 50% of Parkinson's disease patients. Pimavanserin selectively targets serotonin 5-HT2A receptors, which are believed to contribute to the hallucinations and delusions experienced by these patients. Nuplazid was approved by the FDA in 2016, and it has since been prescribed to over 200,000 patients.
Acadia also has a pipeline of other CNS drugs in various stages of development. Its product candidates include:
- Trofinetide: A potential treatment for Rett syndrome, a rare genetic disorder that affects mainly girls and causes developmental and cognitive disabilities.
- ACP-044: A potential treatment for schizophrenia and other psychiatric disorders.
- ACP-319: A potential treatment for major depressive disorder and other mood disorders.
- ACP-105: A potential treatment for Alzheimer's disease and other neurodegenerative disorders.
Acadia has partnerships with several pharmaceutical companies, including Eisai, AstraZeneca, and Neuren Pharmaceuticals, to further develop and commercialize some of its products.
Acadia has experienced significant growth in recent years, with a market capitalization of over $5 billion and a workforce of over 1,300 employees. It has received numerous awards and recognitions for its research and development efforts, including being named one of the World's Most Innovative Companies by Forbes in 2014 and receiving the Prix Galien USA award for Best Biotechnology Product in 201
In addition to its focus on developing innovative CNS drugs, Acadia also prioritizes corporate social responsibility and sustainability. It has implemented various programs to reduce its environmental impact, support local communities, and promote diversity and inclusion within its workforce.
Company Address: 12830 El Camino Real San Diego 92130 CA
Company Phone Number: 558-2871 Stock Exchange / Ticker: NASDAQ ACAD
|
3.85% 
62.27 %